Sanofi (SNYNF)
| Previous close | 96.65 |
| Open | 100.47 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 100.47 - 101.50 |
| 52-week range | 86.12 - 110.45 |
| Volume | |
| Avg. volume | 26,596 |
| Market cap | 128.553B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 26.09 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.06 (4.20%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- Bloomberg
BofA, BNP Poised to Win Lead Roles on $20 Billion Sanofi Spinoff
(Bloomberg) -- Bank of America Corp. and BNP Paribas SA are on the verge of winning lead roles arranging Sanofi’s separation of its consumer-health business, according to people familiar with the matter, in one of the year’s most sought-after banking assignments. Most Read from BloombergIsrael Says a Cease-Fire Plan Backed by Hamas Falls Far ShortAt $2 Million Per Minute, Treasuries Mint Cash Like Never BeforeEx-Trump Controller Says Cohen Repaid From Personal AccountJack Dorsey Leaves Bluesky B
- Insider Monkey
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript May 2, 2024 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $9.55 EPS, expectations were $10.17. Regeneron Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]
- Thomson Reuters StreetEvents
Q1 2024 Kymera Therapeutics Inc Earnings Call
Q1 2024 Kymera Therapeutics Inc Earnings Call
